Skip to Main Content

Shield™ Multi-Cancer Detection (MCD) results report

Shield now offers additional information for 10 cancers.1

The Shield MCD results report is not a part of the FDA approved Shield IVD and has not been cleared or approved by the FDA.

The Shield Multi-Cancer Detection (MCD) results report includes the following 10 cancers1:

Bladder

Liver (Hepatocellular)

Breast

Lung

CRC

Ovarian

Esophageal

Pancreatic

Gastric (Stomach)

Prostate


Overall performance: Shield MCD results report

60%

overall sensitivity
(222/372)1

34%

Stage I/II sensitivity1


84%

Stage III/IV sensitivity1

98.6%

specificity
(436/442)1

87%

primary CSO
accuracy
1,2

tube
73%

sensitivity in cancers without average-risk, standard-of-care screening1,3

Includes bladder, esophageal, gastric, hepatocellular, lung, ovarian, and pancreatic cancers.

74%

sensitivity in the 6 most aggressive cancers (defined as the shortest survival rates)1,4

Includes esophageal, gastric, hepatocellular, lung, ovarian, and pancreatic cancers.

Ask your Shield representative for more information on the Shield MCD results report. Get in touch >

  1. Reference:
  2. 1. He Y, Forouzmand E, Burke J, et al. Validation of a plasma cell-free DNA methylation-based multi-cancer detection test. Abstract 10550. Presented at: 2025 ASCO Annual Meeting; May 30-June 3, 2025; Chicago, IL.
  3. 2. Data on file. Guardant Health, Inc.
  4. 3. US Preventive Services Task Force. Published recommendations, cancer. Accessed August 14, 2025. https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results?topic_status=P&category%5B%5D=15&age_group%5B%5D=10&type%5B%5D=5&searchterm=
  5. 4. National Cancer Institute. Cancer stat facts: common cancer sites. Accessed August 14, 2025. https://seer.cancer.gov/statfacts/html/common.html